SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas selection for the U.S. Armys ALATTIS program to develop next-generation silicon-carbide power semiconductors is driving attention, with traders viewing the award as technology validation and a potential defense-market opening. Some are cautious that it is a prototype-development program with undisclosed financial terms, so its near-term revenue impact is unclear and the initial enthusiasm has met with profit-taking.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quants reported selection by The Clearing House for interoperability in its on-chain money initiative is driving attention, with traders highlighting potential bank adoption and QNTs limited supply. Bulls view the development as a major catalyst, while skeptics question whether the project will create direct demand for the token and point to its future rollout; the discussion also reflects sharp volatility and profit-taking after a steep rally.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiaks Phase 3 DAYBREAK trial met its primary endpoints for two experimental wet AMD treatments, with Zenkuda showing potential for longer intervals between injections and a planned FDA filing adding to optimism. Traders celebrated the sharp repricing and speculated about a short squeeze, while skeptics questioned the drugs advantage over newer competitors and raised concerns about future financing and dilution.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPengs prolonged slide to fresh lows has traders focused on disappointing Q2 results, a weaker Q3 outlook, and concerns about margins and profitability amid pressure on Chinese EV stocks. Frustration and bearish sentiment dominate, though some investors see the robotics business and international growth as underappreciated.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

AstraZenecas strategic equity investment and clinical-trial collaboration with Summit is driving attention, with traders welcoming the added financial backing and validation for ivonescimab. Some are speculating about a future buyout or short squeeze, while others note the deal is an investmentnot an acquisitionand debate how much it changes the drugs clinical and FDA risks.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Reports of production cuts and layoffs at Cleveland-Cliffs Hamilton plant amid tariff-related damage are weighing on sentiment, with traders pointing to the announcement as a concrete concern. The discussion is split between worries about the companys debt and execution and bullish views that strong steel prices and demand could offset the pressure.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FHFA changes allowing lenders to use VantageScore alongside FICO have fueled concern that competition could weaken Fair Isaacs longstanding mortgage-scoring advantage and pricing power. Traders are debating whether the selloff reflects a lasting threat to its moat or an overreaction, with some seeing value in the companys still-strong business.

Anthropic

Anthropics confidential IPO filing and preparations for a potential public debut are driving attention, with traders debating its growth prospects against concerns about lofty valuation, heavy infrastructure spending, and profitability. Some are looking for pre-IPO exposure, while skeptics expect the offering to be overhyped.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

CEO Dave Ricks comments that Lilly may pursue larger acquisitions with cash from its obesity-drug business have renewed discussion of the companys expansion beyond GLP-1s. Traders see the deals as a way to build future growth, while broader conversation weighs Lillys obesity-market strength against competition and its premium valuation.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himaxs potential exposure to AI-related co-packaged optics (CPO/TSMC COUPE) is the dominant topic, with traders anticipating a production ramp and future revenue contribution while debating the timing and whether that opportunity is reflected in the shares. Short-term discussion focuses on volatile, low-volume trading, options positioning, and HIMXs lag versus semiconductor peers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
